Partial Stem Cell Transplant for Sickle Cell Disease

This trial explores a partial stem cell transplant for individuals with severe sickle cell disease or beta-thalassemia who require regular blood transfusions. The goal is to increase the number of donor cells that remain in the body long-term, potentially reducing the need for transfusions. Participants may qualify if they have sickle cell disease with serious complications, such as frequent hospital visits or kidney issues, or if they have beta-thalassemia with significant iron overload. As a Phase 1/Phase 2 trial, this research aims to understand how the treatment works and to measure its effectiveness in an initial group, offering participants a chance to contribute to groundbreaking advancements.

The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

A previous study found abatacept to be safe and effective when used with stem cell transplants. It successfully prevented severe graft-versus-host disease (GVHD), where donor cells attack the recipient's body, achieving a survival rate of over 96% for those receiving the treatment. This makes abatacept a promising option for reducing complications after transplant procedures.

Research has shown that alemtuzumab, another treatment used in transplants, is generally safe for children with sickle cell disease. Successful engraftment occurred in about 95% of patients without severe side effects. However, reports have noted serious side effects, including immune system problems and reactions during infusion.

Studies have demonstrated that increasing the dose of total body irradiation (TBI) enhances transplant success while maintaining safety. Specifically, increasing TBI from 200 to 400 cGy improved engraftment and was well-tolerated, with most patients not experiencing severe side effects.

Researchers are excited about this approach to treating sickle cell disease because it uses partial stem cell transplants from matched related donors, which could offer a more sustainable solution than current treatments like hydroxyurea and blood transfusions. Unlike standard treatments that mainly address symptoms, this method aims to tackle the root cause of the disease by replacing faulty blood-forming stem cells. The inclusion of drugs like abatacept and alemtuzumab, along with total body irradiation, is designed to prepare the body for the transplant, potentially reducing the risk of rejection and improving the success rate of the transplant. This innovative strategy has the potential to offer a long-term cure rather than temporary relief.

This trial will evaluate partial stem cell transplants for treating sickle cell disease. Studies have shown promising results, with a survival rate without sickle cell symptoms at 85% and an overall survival rate of 94%. In this trial, some participants will receive Abatacept, which effectively prevents graft versus host disease (GVHD), a condition where transplanted cells attack the body. Alemtuzumab, used to prepare the body for the transplant, has demonstrated good results in previous studies. Total body irradiation (TBI) will also be applied at different doses to support the transplant process. Together, these treatments aim to improve success rates for patients with severe sickle cell disease.⁵⁶⁷⁸⁹